Daiichi gets Japanese rights to Amgen's biosimilars

Amgen Inc. (NASDAQ:AMGN) granted Daiichi Sankyo Co. Ltd. (Tokyo:4568) exclusive rights to commercialize nine biosimilars in Japan. Amgen will remain

Read the full 200 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE